Demand Brands (OTCMKTS:DMAN – Get Free Report) and Incannex Healthcare (NASDAQ:IXHL – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.
Profitability
This table compares Demand Brands and Incannex Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Demand Brands | N/A | N/A | N/A |
| Incannex Healthcare | N/A | -81.01% | -76.11% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Demand Brands and Incannex Healthcare, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Demand Brands | 0 | 0 | 0 | 0 | 0.00 |
| Incannex Healthcare | 1 | 0 | 1 | 0 | 2.00 |
Institutional & Insider Ownership
98.1% of Demand Brands shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 2.2% of Demand Brands shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Demand Brands and Incannex Healthcare”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Demand Brands | N/A | N/A | N/A | ($0.59) | -0.00 |
| Incannex Healthcare | $90,000.00 | 484.12 | -$46.88 million | ($1.55) | -2.35 |
Demand Brands has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Demand Brands, indicating that it is currently the more affordable of the two stocks.
Summary
Demand Brands beats Incannex Healthcare on 6 of the 10 factors compared between the two stocks.
About Demand Brands
Demand Brands, Inc. focuses on developing electroseismic applications and drone programs technologies for the energy industry. The company is based in Santa Monica, California.
About Incannex Healthcare
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.
Receive News & Ratings for Demand Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Demand Brands and related companies with MarketBeat.com's FREE daily email newsletter.
